It has been broadly experienced that targeting hallmarks of cancer cells by inhibiting angiogenesis, blocking antiapoptotic proteins or inhibiting tumor-associated receptor tyrosine kinases that provide survival signals is most often circumvented by resistance mechanisms in malignant cells during tumor progression. This evidence concerns the gene NTRK1 and cancer.